Literature DB >> 29536061

Laparoscopic pancreaticoduodenectomy for renal cell carcinoma metastasized to ampulla of Vater: A case report and literature review.

Dominic Cheong1, Seoung Yoon Rho2,3, Ji Hong Kim2,3, Chang Moo Kang2,3, Woo Jung Lee2,3.   

Abstract

Renal cell carcinoma is the most common primary renal neoplasm in adults. Although renal cell carcinoma is known to spread to unusual sites, the ampulla of Vater is considered a rare site for metastasis. Here we present a case of renal cell carcinoma metastasized to the ampulla of Vater along with literature review. A 62-year-old Korean male had a history of hypertension and right-sided renal cell carcinoma diagnosed in September 2004, for which he underwent right radical nephrectomy in October 2004. The patient eventually underwent laparoscopic pylorus-preserving total pancreaticoduodenectomy in January 2017. The surgery was successful without postoperative complications. Previous studies have shown that surgical resection for solitary metastases of renal cell carcinoma can provide favorable survival rates. Our case report provides evidence that pancreaticoduodenectomy may be a treatment of choice for suitable patients with solitary renal cell carcinoma ampullary metastasis. A minimally invasive approach may result in early recovery of patient to be suitable for subsequent chemotherapy. Further evidence is needed to address the exact role of minimally invasive pancreaticoduodenectomy in renal cell carcinoma metastasized to the ampulla of Vater.

Entities:  

Keywords:  Laparoscopic; Pancreas metastasis; Pancreaticoduodenectomy; Renal cell carcinoma

Year:  2018        PMID: 29536061      PMCID: PMC5845616          DOI: 10.14701/ahbps.2018.22.1.83

Source DB:  PubMed          Journal:  Ann Hepatobiliary Pancreat Surg        ISSN: 2508-5859


INTRODUCTION

Renal cell carcinoma is the most common primary renal neoplasm in adults.1 It accounts for approximately 2–4% of all adult malignancies.23 Surgery may be curative if the disease is localized. However, many patients eventually experience relapse. The most common metastasis sites for renal cell carcinoma are lungs, bones and liver.4 Although renal cell carcinoma is known to spread to unusual sites, the ampulla of Vater is considered a rare metastasis site. When this occurs, it may be indistinguishable from primary ampullary tumor during initial presentation. Interestingly, renal cell carcinoma is not the only malignancy known to spread to the ampulla of Vater. Melanomas,56 breast carcinomas,78 squamous cell carcinoma of the larynx,9 and cervical carcinoma10 can also spread to the ampulla of Vater. Despite advances in laparoscopic techniques and experiences, it remains controversial whether laparoscopic pancreaticoduodenectomy should be regarded as a safe and effective surgical approach for selected patients.11 In this case report, we present a patient with renal cell carcinoma metastasized to the ampulla of Vater who was successfully treated with laparoscopic pancreaticoduodenectomy. To the best of our knowledge, this is the first report of laparoscopic pancreaticoduodenectomy for renal cell carcinoma metastasized to the ampulla of Vater. We also provided a brief literature review.

CASE

Patient description

A 62-year-old Korean male patient presented with jaundice and dark urine in December 2016. He had a history of hypertension and right-sided renal cell carcinoma diagnosed in September 2004, for which he underwent right radical nephrectomy in October 2004. Pathological analysis reported a conventional type, Fuhrman nuclear grade 2 tumor with hemorrhage and sclerosis (T1N0M0). He had no known family history of renal malignancy. He did not smoke. He did not excessively drink alcohol either.

Preoperative findings

Physical examination did not yield any significant findings. Laboratory results showed the following: aspartate transaminase (AST), 169 U/L; alanine transaminase (ALT), 213 U/L; total bilirubin, 2.4 mg/dl; gamma glutamyl transferase (γ-GT), 992 U/L; lipase, 221 U/L; amylase, 155 U/L; alkaline phosphatase (ALP), 650 U/L; carcinoembryonic antigen (CEA), 4.21 ng/ml; and cancer antigen 19-9 (CA19-9), 10.9 U/ml. Magnetic resonance imaging (MRI) pancreaticobiliary, positron emission tomography-computed tomography (PET-CT), and endoscopic retrograde cholangiopancreatography (ERCP) showed a firm whitish mass from the duodenum superior duodenal angle to the ampulla of Vater (Fig. 1). Endoscopic ultrasound-fine needle aspiration (EUS-FNA) cytology analysis revealed clusters of atypical pancreaticobiliary epithelial cells suspicious for malignancy. The initial impression was ampulla of Vater cancer with duodenal and pancreatic extension. Differential diagnoses of duodenal cancer or pancreatic cancer were also considered.
Fig. 1

(A) Endoscopic view showing whitish firm mass from the superior duodenal angle to the ampulla of Vater. (B) Preoperative MRI pancreaticobiliary T2 weighted image showing a papillary shaped mass in the ampulla of Vater with duodenal and pancreas extension. (C) PET-CT showing increased FDG uptake of the tumor involving the duodenum and pancreatic head. T, tumor.

Operation and pathologic findings

The patient underwent laparoscopic pylorus preserving total pancreaticoduodenectomy in January 2017. As a result of the previous operation, there were severe adhesions at retroperitoneum and previous renal vein ligation sites. The colon and duodenum were rotated due to the absence of the right kidney. It was difficult to dissect the superior mesenteric artery (SMA) lateral margin due to adhesion after the previous retroperitoneal space dissection. After the resection phase, pancreaticojejunostomy (duct-to-mucosa) and hepaticojejunosotmy were done via laparoscopic approach. Duodenojejunostomy was done through a small mini laparotomy around the umbilicus where surgical specimen needed to be removed. Operation time was 510 min and estimated blood loss was 400 ml. Gross findings for the specimen included a protruding mass on the ampulla of Vater (Fig. 2). Pathological examination revealed metastatic clear cell renal carcinoma involving the duodenum, ampulla of Vater, and pancreas (Fig. 3). The tumor size was 5.4 cm in maximum diameter. Lymphovascular invasion was noted without perineural invasion. All resection margins including the common bile duct, pancreatic duct, duodenum, and retroperitoneum were negative for carcinoma cells. Total retrieved lymph nodes were 13 without any positive nodes.
Fig. 2

Operative findings after resection phase. (A) Bile duct was clamped and the gastroduodenal artery (GDA) was ligated. (B) Reconstruction phase of laparoscopic pancreaticojejunostomy (duct-to-mucosa). (C) Reconstruction phase of laparoscopic hepaticojejunostomy. (D) Specimen gross finding showing the protruding mass on the ampulla of Vater. BD, bile duct; GDA, gastroduodenal artery; Pan, pancreas; PV, portal vein; J, jejunum; T, tumor; CBD, common bile duct; AoV, ampulla of Vater.

Fig. 3

Pathologic report. (A) Tumor invading the proper duodenum muscle layer (×12.5). (B) Characteristic appearance of renal clear cell carcinoma with clear cytoplasm arranged in nests (×100). Dm, Duodenum mucosa; BG, Brunner's gland; Pm, Proper muscle layer; T, Tumor.

Postoperative recovery

The length of hospital stay was 12 days postoperatively. During hospital stay, there were no significant postoperative complications. The patient was regularly followed up in Urology and Surgery Outpatient Departments to consider adjuvant chemotherapy.

Literature review

Based on literature review, a total of 11 patients with renal cell carcinoma metastasized to the ampulla of Vater have been reported (Table 1). Nine patients were males and three were females. Their mean age was 62.6±11.6 years. These patients had relatively early stage renal cell carcinoma when initial nephrectomy was performed. Mean time interval from initial nephrectomy to diagnosis of metastatic renal cell carcinoma to the ampulla of Vater was 82.5±64.9 months. The most common symptom was obstructive jaundice. Palliative procedures such as ERCP with sphincterotomy, endoscopic ampullectomy, percutaneous transhepatic biliary drainage with stent insertion, and choledochoduodenostomy were performed in five patients. Pancreaticoduodenectomy was performed in seven patients, including the present case (Table 2). Mean overall survival time for patients who had metastatic renal cell carcinoma to the ampulla of Vater from initial nephrectomy was 106.3±57.9 months (95% CI: 72.6–137.8 months), excluding two cases without mentioning the survival time. Mean survival after a resection for metastatic ampulla of Vater cancer was found to be superior to that with palliative management (137±40.1 months vs. 59.5±50.1 months; p=0.00134). However, there was no statistically significant difference in overall survival between the two groups according to age, gender, or interval time from initial nephrectomy to diagnosis of metastasis to the ampulla of Vater (Fig. 4).
Table 1

Cases of renal cell carcinoma metastasized to the ampulla of Vater

*Metastatic cancer to the ampulla of Vater was discovered at the same time as RCC

RCC, Renal cell carcinoma

Table 2

Summary of specific symptoms, treatment, interval time to recurrence and overall survival in each case

*Metastatic cancer to the ampulla of Vater was discovered at the same time as renal cell cancer

ERCP, endoscopic retrograde cholangiopancreatography; PPPD, pylorus-preserving pancreaticoduodenectomy; IFN, interferon

Fig. 4

Literature review-based oncologic outcome analysis of patients with metastatic renal cell carcinoma to the ampulla of Vater. (A) Overall survival between patients who underwent palliative procedures and those who underwent resectional operations. (B) Overall survival between the two groups of patients according to age. (C) Overall survival between the two groups of patients according to gender. (D) Overall survival between the two groups of patients according to the interval time from initial nephrectomy to diagnosis of metastasis.

DISCUSSION

Here we report a patient with right-sided renal cell carcinoma metastasized to the ampulla of Vater presenting with jaundice 12 years after initial treatment for renal malignancy. To the best of our knowledge, this is the first case of renal cell carcinoma metastasized to the ampulla of Vater treated with laparoscopic pylorus-preserving total pancreaticoduodenectomy among a handful of similar cases reported in the literature. Most patients had left-sided renal cell carcinoma. They were middle aged to elderly males. Based on our observation, the most common presentations were obstructive jaundice and gastrointestinal bleeding. Other presentations included malabsorption, fatigue, weight loss, abdominal pain/discomfort and recurrent cholangitis. The mean time from initial nephrectomy to diagnosis of metastatic ampulla of Vater cancer was 82.5±64.9 months. The longest was 210 months. The mean time from initial nephrectomy to diagnosis of metastatic ampulla of Vater cancer is longer than that for metastases to other regions, most of which is within the first two to three years following nephrectomy.11 It is known that a prolonged interval between nephrectomy and appearance of metastasis is associated with better prognosis.12 Based on literature review, this trend was seen in most cases, but not in all cases. Except for two cases that did not mention the overall survival time, patients who underwent resectional operation for metastatic ampulla of Vater cancer had favorable long-term survival compared to those in the palliative management group. However, we could not find any statistically significant difference in survival according to gender, age, or interval time from initial nephrectomy to diagnosis of metastatic lesions. There was no association between initial stage of primary disease and interval time to recurrence either. Solitary metastases of renal cell carcinoma have been treated successfully by surgical resection, achieving 5-year survival rates of 24%–60%.111314 In one study of twelve patients who underwent pancreaticoduodenectomy for metastatic ampullary and pancreatic tumors, surgical resection for solitary metastases of renal cell carcinoma provided favorable survival rates.15 Based on literature review, most patients who received surgery for solitary metastasis to the ampulla of Vater had good post-operative survival. Due to the lack of data, we were unable to calculate the exact average survival in number of years. Nonetheless, we believe that pancreaticoduodenectomy is a treatment choice for suitable patients with solitary ampullary metastasis of renal cell carcinoma. Minimally invasive approach may provide patient a potential chance for early recovery to be suitable for subsequent chemotherapy. Further evidence is needed to address the exact role of minimally invasive pancreaticoduodenectomy in renal cell carcinoma metastasized to the ampulla of Vater.
  25 in total

1.  Ampulla of Vater metastasis from recurrent uterine cervix carcinoma presenting as groove pancreatitis.

Authors:  Tae Hoon Lee; Sang-Heum Park; Chang Kyun Lee; Suck-Ho Lee; Il-Kwun Chung; Sun-Joo Kim; Sang Won Kim
Journal:  Gastrointest Endosc       Date:  2010-10-15       Impact factor: 9.427

2.  Metastasis of renal cell carcinoma to the duodenal papilla.

Authors:  Sudipta Dhar Chowdhury; Dipti Masih; Gaurav Chawla; Sandip Pal; Reuben Thomas Kurien; Joby Augustine
Journal:  Indian J Gastroenterol       Date:  2014-09

3.  Ampullary metastasis from breast cancer: an unusual finding.

Authors:  R F Rego; M Atiq; N Velchala; D Nevin; D P McElreath; W D McKnight; F Aduli
Journal:  Endoscopy       Date:  2009-10-28       Impact factor: 10.093

Review 4.  Epidemiologic aspects of renal cell carcinoma.

Authors:  Joseph K McLaughlin; Loren Lipworth; Robert E Tarone
Journal:  Semin Oncol       Date:  2006-10       Impact factor: 4.929

5.  Pathological features of renal neoplasms classified by size and symptomatology.

Authors:  Bruce Schlomer; Robert S Figenshau; Yan Yan; Ramakrishna Venkatesh; Sam B Bhayani
Journal:  J Urol       Date:  2006-10       Impact factor: 7.450

6.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

7.  Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma--results from a comprehensive multi-centre database (CORONA/SATURN-Project).

Authors:  Sabine D Brookman-May; Matthias May; Shahrokh F Shariat; Giacomo Novara; Richard Zigeuner; Luca Cindolo; Ottavio De Cobelli; Cosimo De Nunzio; Sascha Pahernik; Manfred P Wirth; Nicola Longo; Alchiede Simonato; Sergio Serni; Salvatore Siracusano; Alessandro Volpe; Giuseppe Morgia; Roberto Bertini; Orietta Dalpiaz; Christian Stief; Vincenzo Ficarra
Journal:  BJU Int       Date:  2013-07-25       Impact factor: 5.588

8.  Management of renal cell carcinoma with solitary metastasis.

Authors:  Yuvaraja B Thyavihally; Umesh Mahantshetty; Ravichand S Chamarajanagar; Srinivas G Raibhattanavar; Hemant B Tongaonkar
Journal:  World J Surg Oncol       Date:  2005-07-20       Impact factor: 2.754

9.  A Case of Metastatic Renal Cell Cancer Presenting as Jaundice.

Authors:  MinYuen Teo; Barbara Ryan; Niall Swan; Ray S McDermott
Journal:  World J Oncol       Date:  2010-11-02

10.  Squamous cell carcinoma of the larynx metastasized to the ampulla of Vater. Report of a case.

Authors:  Abdullah Büyükçelik; Arzu Ensari; Mustafa Sarioğlu; Abdurrahman Işikdogan; Fikri Içli
Journal:  Tumori       Date:  2003 Mar-Apr
View more
  3 in total

1.  Surgery for metastatic renal cell carcinoma in the pancreatic head: A case report and literature review.

Authors:  Sungho Jo; In Jun Yang; Sanghyun Song
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2019-02-28

2.  Secondary Tumors of the Ampulla of Vater: A Tale of Two Cases.

Authors:  Jafer Ali; Asad Khan; Mohamed H Ahmed; Ravi Madhotra
Journal:  J Lab Physicians       Date:  2021-07-29

3.  Clear Cell Renal Cell Carcinoma Metastasized to the Ampulla of Vater 16 Years after Nephrectomy-A Rare Case.

Authors:  Jun Lu; Weijiang Zhou; Xuyong Wei; Kai Wang; Lixin Zhou; Xiao Xu
Journal:  Diagnostics (Basel)       Date:  2022-02-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.